Results 141 to 150 of about 6,532 (197)
Repurposing Ivacaftor for treatment of Staphylococcus aureus infections
International Journal of Antimicrobial Agents, 2017 Drug repurposing of non-antimicrobials is a novel method to augment a seriously depleted drug pipeline for targeting drug-resistant pathogens. This article highlights the potent antimicrobial activity of Ivacaftor against Staphylococcus aureus, including
Ritesh Thakare +2 more
exaly +2 more sources
Real-Life Safety and Effectiveness of Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis
American Journal of Respiratory and Critical Care Medicine, 2020 International audienceRationale: Lumacaftor-ivacaftor is a CFTR (cystic fibrosis transmembrane conductance regulator) modulator combination recently approved for patients with cystic fibrosis (CF) homozygous for the Phe508del mutation.Objectives: To ...
Marlene Murris-Espin +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs of the Future, 2012
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
null Raju, S.V., null Rowe, S.M.
+4 more sources
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
null Raju, S.V., null Rowe, S.M.
+4 more sources